Alzamend Neuro is trading at $1.43, up 6.72%, with no confirmed catalyst identified. - No new company announcement was identified for October 9; the latest listed release was September 16. - A Zacks Rank upgrade to #2 (Buy), published October 8, cited rising earnings estimates, but no source established it as the direct cause of the October 9 move. - Broader indices were modestly positive while the biotech sector was down; neither clearly explains the gain.